The development of drug delivery platforms that offer sustained release of therapeutic agents in the retina represents a vital evolution in ophthalmic practice.
While the ongoing emergence of effective drugs and biologics for the treatment of retinal conditions has been a great boon to our patients, the burden of frequent intravitreal injections poses challenges to patient adherence and can result in suboptimal outcomes (Holz et al.).
Furthermore, sustained-release delivery of therapeutic agents to target tissues can provide consistent exposure of therapeutic agents with short half-lives that